PRESS RELEASE

from SARTORIUS STED BIO (EPA:DIM)

Sartorius Stedim Biotech SA: Information on Document Availability

Sartorius Stedim Biotech SA
Sartorius Stedim Biotech SA: Information on Document Availability

19-Jul-2024 / 09:50 CET/CEST
Dissemination of a French Regulatory News, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


Aubagne, July 19, 2024

 

 

Information on Document Availability

The report on the first half 2024 results of Sartorius Stedim Biotech Group (Paris: DIM) is now available at:

https://www.sartorius.com/en/company/investor-relations/sartorius-stedim-biotech-sa-investor-relations

It contains the following information:

  • Business development for the period of January to June 2024 as well as the 2024 full year forecast for the Sartorius Stedim Biotech Group
  • Consolidated financial statements for the period ended June 30, 2024

 

A profile of Sartorius Stedim Biotech

Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider

of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture

biotech medications, such as cell and gene therapies, safely, rapidly, and economically. The shares of

Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach

with manufacturing and R&D sites as well as sales entities in Europe, North America, and Asia. Sartorius

Stedim Biotech regularly expands its portfolio through acquisitions of complementary technologies. In

2023, the company generated sales revenue of around 2.8 billion euros. By the end of 2023, more than

10,600 employees were working for customers around the globe.

 

Contact

Petra Müller     

Head of Investor Relations   

+49 (0)551.308.6035      

petra.mueller2@sartorius.com   

 

 


Regulatory filing PDF file

File: 2024_SSB_Document availability H1_en


Language:English
Company:Sartorius Stedim Biotech SA
Avenue de Jouques
13781 Aubagne
France
Phone:+33 44 284 5600
E-mail:sartorius.presse@sartorius.com
Internet:www.sartorius-stedim.com
ISIN:FR0013154002
Euronext Ticker:DIM
AMF Category:Half-yearly financial and audit reports/reduced exams / Terms of availability of the half-yearly financial report
EQS News ID:1950133
 
End of AnnouncementEQS News Service

1950133  19-Jul-2024 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1950133&application_name=news&site_id=symex~~~af100301-a623-4c64-8f3d-90fc88eca9e6
See all SARTORIUS STED BIO news